What NeuroOne Medical Technologies Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 2 |
| Sells | 0 | 6 |
| Total trades | 1 | 22 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 33,333 | 229,655 |
| Disposed | 0 | 29,215 |
| Net activity | +33,333 | +200,441 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Wambeke David J. | Chief Business Officer | Aug 27 | Open-market buy · P | +33,333 | $2.01 | +$67K | 199,999 |
| Christianson Mark | Market Development Director | Jun 30 | Open-market sale · S | −10,000 | $3.18 | −$31.8K | 20,692 |
| Andrle Edward | Director | Apr 03 | Grant / award · A | +41,929 | — | — | 133,932 |
| Buckman Paul | Director | Apr 03 | Grant / award · A | +41,929 | — | — | 178,733 |
| Mathiesen Jeffrey S | Director | Apr 03 | Grant / award · A | +41,929 | — | — | 156,343 |
| Mills Jason Richard | Director | Apr 03 | Grant / award · A | +41,929 | — | — | 49,687 |
| Christianson Mark | Business Development Director | Mar 31 | Withheld — tax / exercise cost · F | −253 | $0.78 | −$197 | 198,667 |
| Rosa David A | CEO and President | Mar 31 | Withheld — tax / exercise cost · F | −2,458 | $0.78 | −$1.91K | 1,080,132 |
| Mertens Steve | Chief Technology Officer | Mar 31 | Withheld — tax / exercise cost · F | −906 | $0.78 | −$704 | 152,141 |
| Christianson Mark | Business Development Director | Mar 30 | Open-market sale · S | −15,363 | $0.74 | −$11.4K | 198,920 |
| Christianson Mark | Business Development Director | Mar 13 | Open-market sale · S | −100 | $0.80 | −$80 | 214,283 |
| Christianson Mark | Business Development Director | Mar 12 | Open-market sale · S | −817 | $0.80 | −$654 | 214,383 |
| Christianson Mark | Business Development Director | Mar 11 | Open-market sale · S | −2,109 | $0.80 | −$1.69K | 215,200 |
| Christianson Mark | Business Development Director | Mar 10 | Open-market sale · S | −11,611 | $0.80 | −$9.29K | 217,309 |
| Wambeke David J. | Chief Business Officer | Mar 01 | Open-market buy · P | +1,000,000 | $0.67 | +$670K | 1,000,000 |
| Christianson Mark | Business Development Director | Feb 18 | Withheld — tax / exercise cost · F | −1,812 | $0.68 | −$1.23K | 228,920 |
| Rosa David A | CEO and President | Feb 18 | Withheld — tax / exercise cost · F | −71,325 | $0.68 | −$48.5K | 1,082,590 |
| Mertens Steve | Chief Technology Officer | Feb 18 | Withheld — tax / exercise cost · F | −7,376 | $0.68 | −$5.02K | 153,047 |
| Christianson Mark | Business Development Director | Dec 31 | Withheld — tax / exercise cost · F | −253 | $0.76 | −$192 | 230,732 |
| Rosa David A | CEO and President | Dec 31 | Withheld — tax / exercise cost · F | +2,458 | $0.76 | +$1.86K | 1,153,915 |
Loading...